Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Hormonal Therapy for the Treatment of Primary HER2-Positive Breast Cancer: One More Step Toward Chemotherapy-Free Therapy

被引：19
作者：
Prat, Aleix [1 ]
Baselga, Jose [2 ]
机构：
[1] Vall dHebron Inst Oncol, Barcelona, Spain
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 14期
关键词：
PHASE-II; TRASTUZUMAB RESISTANCE; ADJUVANT CHEMOTHERAPY; PLUS TRASTUZUMAB; OPEN-LABEL; LAPATINIB; MULTICENTER; PERTUZUMAB; COMBINATION; DOCETAXEL;
D O I：
10.1200/JCO.2012.48.4998
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1703 / 1706
页数：4
相关论文
共 35 条
[1]  
[Anonymous], GUID IND PATH COMPL
[2]  
[Anonymous], 35 ANN SAN ANT BREAS
[3]   Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy [J].
Arpino, Grazia ;
Gutierrez, Carolina ;
Weiss, Heidi ;
Rimawi, Mothaffar ;
Massarweh, Suleiman ;
Bharwani, Lavina ;
De Placido, Sabino ;
Osborne, C. Kent ;
Schiff, Rachel .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (09) :694-705
[4]   Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].
Baselga, Jose ;
Bradbury, Ian ;
Eidtmann, Holger ;
Di Cosimo, Serena ;
de Azambuja, Evandro ;
Aura, Claudia ;
Gomez, Henry ;
Dinh, Phuong ;
Fauria, Karine ;
Van Dooren, Veerle ;
Aktan, Gursel ;
Goldhirsch, Aron ;
Chang, Tsai-Wang ;
Horvath, Zsolt ;
Coccia-Portugal, Maria ;
Domont, Julien ;
Tseng, Ling-Min ;
Kunz, Georg ;
Sohn, Joo Hyuk ;
Semiglazov, Vladimir ;
Lerzo, Guillermo ;
Palacova, Marketa ;
Probachai, Volodymyr ;
Pusztai, Lajos ;
Untch, Michael ;
Gelber, Richard D. ;
Piccart-Gebhart, Martine .
LANCET, 2012, 379 (9816) :633-640
[5]   Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].
Baselga, Jose ;
Cortes, Javier ;
Kim, Sung-Bae ;
Im, Seock-Ah ;
Hegg, Roberto ;
Im, Young-Hyuck ;
Roman, Laslo ;
Pedrini, Jose Luiz ;
Pienkowski, Tadeusz ;
Knott, Adam ;
Clark, Emma ;
Benyunes, Mark C. ;
Ross, Graham ;
Swain, Sandra M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119
[6]   Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study [J].
Blackwell, Kimberly L. ;
Burstein, Harold J. ;
Storniolo, Anna Maria ;
Rugo, Hope S. ;
Sledge, George ;
Aktan, Gursel ;
Ellis, Catherine ;
Florance, Allison ;
Vukelja, Svetislava ;
Bischoff, Joachim ;
Baselga, Jose ;
O'Shaughnessy, Joyce .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2585-2592
[7]  
*CLINICALTRIALS, ALTTO ADJ LAP TRAST
[8]  
ClinicalTrials.gov, STUD PERT ADD CHEM H
[9]  
Cortazar P, 2012, 35 ANN SAN ANT BREAS
[10]   Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer [J].
Cortes, Javier ;
Fumoleau, Pierre ;
Bianchi, Giulia Valeria ;
Petrella, Teresa M. ;
Gelmon, Karen ;
Pivot, Xavier ;
Verma, Shailendra ;
Albanell, Joan ;
Conte, Pierfranco ;
Lluch, Ana ;
Salvagni, Stefania ;
Servent, Veronique ;
Gianni, Luca ;
Scaltriti, Maurizio ;
Ross, Graham A. ;
Dixon, Joanna ;
Szado, Tania ;
Baselga, Jose .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) :1594-1600
1234